Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Leukenib 100. Please consult your doctor.
CONSULT YOUR DOCTOR
Leukenib 100 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
CONSULT YOUR DOCTOR
Leukenib 100 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Lactating women should not breastfeed while using this drug and one month after stopping it.
UNSAFE
Leukenib 100 may cause side effects which could affect your ability to drive.
CAUTION
Leukenib 100 should be used with caution in patients with kidney disease. Dose adjustment of Leukenib 100 may be needed. Please consult your doctor.
CAUTION
Leukenib 100 should be used with caution in patients with severe liver disease. Dose adjustment of Leukenib 100 may be needed. Please consult your doctor.
Medicine Overview of Leukenib 100mg Tablet
Introduction
Leukenib 100 belongs to the class of medicines known as tyrosine kinase inhibitors. It is used in the treatment of blood cancer (chronic myeloid leukaemia and Acute lymphocytic leukemia) and gastrointestinal stromal tumor. Leukenib 100 should be taken with food, but better to have it same time every day to get the most benefit. You should continue to take it as long as your doctor advises for it. The duration of treatment varies according to your need and response to treatment. Taking it in the wrong way or taking too much can cause very serious side effects. It may take...
... Show moreUses of Leukenib 100
- Blood cancer (Chronic myeloid leukaemia)
- Blood cancer (Acute lymphocytic leukemia)
- Gastrointestinal stromal tumour
Side effects of Leukenib 100
Common
- Abdominal pain
- Diarrhea
- Fatigue
- Muscle cramp
- Musculoskeletal (bone, muscle or joint) pain
- Nausea
- Rash
- Vomiting
How to use Leukenib 100
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Leukenib 100 is to be taken with food.
How Leukenib 100 works
Leukenib 100 is an anti-cancer medication. A protein enzyme, bcr-abl tyrosine kinase, responsible for the growth of abnormal proliferation of cancer cells. This medicine inhibits the proliferation and induces apoptosis (planned cell death) in bcr-abl positive cells (cancer cells). This is how it works to stop or slow the spread of cancer.
What if you forget to take Leukenib 100?
If you miss a dose of Leukenib 100, skip it and continue with your normal schedule. Do not double the dose.
Quick Tips
- Always take it with food and a full glass of water to prevent nausea.
- It may cause dizziness or blurred vision. Do not drive or do anything requiring concentration until you know how it affects you.
- Water retention and swelling are very common side effects of Leukenib 100. Notify your doctor if you have unexpected rapid weight gain.
- Do not change the dose or discontinue use without consulting your doctor.
- Notify your doctor about all the medications you are taking, including over the counter medicines and dietary supplements.
- Your doctor may get regular blood tests done to monitor your liver function and the number of blood cells in your blood.
Brief Description
Indication
Chronic myeloid leukaemia, Acute lymphoblastic leukaemia, Myelodysplastic disease, Hypereosinophilic syndrome, Mastocytosis, Dermatofibrosarcoma protuberans, Malignant gastrointestinal stromal tumours
Administration
Should be taken with food and large glass of water.
Adult Dose
Acute Lymphoblastic Leukemia Indicated for adults with relapsed or refractory Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) 600 mg PO qDay Myelodysplastic/Myeloproliferative Diseases Indicated in adults with myelodysplastic/ myeloproliferative diseases associated with platelet-derived growth factor receptor gene re-arrangements as determined with an FDA-approved test 400 mg PO qDay Hypereosinophilic Syndrome/Eosinophilic Leukemia Indicated for adults with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR-alpha fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR-alpha fusion kinase negative or unknown 400 mg PO qDay In patients with demonstrated...
... Show moreChild Dose
Chronic Myeloid Leukemia
Indicated for newly diagnosed adult and pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
1 year: 340 mg/m²/day PO; not to exceed 600 mg/day
Acute Lymphoblastic Leukemia
Indicated for treatment of newly diagnosed children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)
1 year: 340 mg/m²/day PO; not to exceed 600 mg/day
Contraindication
Hypersensitivity. Lactation.
Mode of Action
Imatinib, is a tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It blocks proliferation and induces apoptosis in BCR-ABL positive cell lines, as well as fresh leukaemic cells from Philadelphia chromosome positive CML. Imatinib also inhibits receptor kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, PDGF- and SCF-mediated cellular events.
Precaution
Cardiac disease or increased risk for CHF. Monitor for signs of severe fluid retention. Monitor CBC regularly. Renal and hepatic impairment. Monitor LFTs. Pregnancy.
Lactation: Imatinib and its active metabolite are excreted into human milk; advise a lactating woman not to breastfeed during treatment and for 1 month after last dose
Side Effect
>10%
Edema (53%),Neutropenia (Grade 3: 7-27%; Grade 4: 3-48%),Nausea (43%),Muscle cramps (35%),Musculoskeletal pain (34%),Thrombocytopenia (Grade 3: 1-31%; Grade 4: 1-34%),Rash (32%),Fatigue (31%),Diarrhea (30%),Headache (29%),Arthralgia (27%),Abd pain (23%),Myalgia (21%),Nasopharyngitis (19%),Hemorrhage (19%),Vomiting (15%),Dyspepsia (15%),Cough (13%),Dizziness (13%),URT infection (13%),Fever (12%),Weight gain (12%),Hepatotoxicity (6-12%),Insomnia (11%)
1-10%
Flushing,Palpitation,Dry skin,Erythema,Metabolic hyperglycemia,Stomatitis/mucositis,Lymphopenia
<1%
Aplastic anemia,Atrial fibrillation,Avascular necrosis,Cardiac failure,Cardiogenic shock,Embolism,Eosinophilia
Potentially Fatal: Hepatotoxicity, cerebral oedema, increased intracranial pressure, papilloedema. Severe fluid retention resulting in pleural and pericardial effusion, pulmonary oedema and ascites. Rarely, GI perforation.
Interaction
Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, macrolide antibiotics). Reduced serum levels w/ CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin). May increase serum levels of substrates of CYP3A4 (e.g. ciclosporin, pimozide, triazolo-benzodiazepines, dihydropyridine Ca channel blockers, certain statins), CYP2C9 (e.g. warfarin) and CYP2D6.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
